Fumi Takahashi-Yanaga


Affiliation: Kyushu University
Country: Japan


  1. request reprint
    Takahashi Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008;20:581-9 pubmed
    ..This review highlights the regulatory mechanisms of cyclin D1 expression level, with special attention to the involvement of GSK-3beta. ..
  2. Kubokura N, Takahashi Yanaga F, Arioka M, Yoshihara T, Igawa K, Tomooka K, et al. Differentiation-inducing factor-3 inhibits intestinal tumor growth in vitro and in vivo. J Pharmacol Sci. 2015;127:446-55 pubmed publisher
    ..These data suggest that DIF-3 inhibits intestinal cancer cell proliferation in vitro and in vivo, probably by mechanisms similar to those identified in DIF-1 actions, and that DIF-3 may be a potential novel anti-cancer agent. ..
  3. request reprint
    Takahashi Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, et al. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem. 2003;278:9663-70 pubmed
    ..These results suggested that DIF-3 activates GSK-3beta to accelerate the proteolysis of cyclin D1 and that this mechanism is involved in the DIF-3-induced G(0)/G(1) arrest in mammalian cells. ..
  4. Takahashi Yanaga F, Yoshihara T, Jingushi K, Miwa Y, Morimoto S, Hirata M, et al. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochem Biophys Res Commun. 2008;377:1185-90 pubmed publisher
    ..Our results suggest that TCF-1 and TCF-4 degradation may involve the inhibition of the Wnt/beta-catenin signaling pathway induced by celecoxib. ..
  5. Noma T, Takahashi Yanaga F, Arioka M, Mori Y, Sasaguri T. Inhibition of GSK-3 reduces prostaglandin E2 production by decreasing the expression levels of COX-2 and mPGES-1 in monocyte/macrophage lineage cells. Biochem Pharmacol. 2016;116:120-9 pubmed publisher
    ..These results suggested that GSK-3 plays a key role in PGE2 production by increasing COX-2 and mPGES-1 probably through Egr-1-mediated transcription and GSK-3 inhibitors may be potential as novel anti-inflammatory drugs. ..
  6. Nagano A, Arioka M, Takahashi Yanaga F, Matsuzaki E, Sasaguri T. Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes. J Pharmacol Sci. 2017;133:18-24 pubmed publisher
    ..These results suggest that celecoxib inhibits osteoblast maturation by suppressing Wnt target genes, and this could be the mechanism that NSAIDs inhibit bone formation and fracture healing. ..
  7. request reprint
    Takahashi Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, Ohta M, et al. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:2095-107 pubmed
  8. request reprint
    Takahashi Yanaga F, Shiraishi F, Hirata M, Miwa Y, Morimoto S, Sasaguri T. Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. Biochem Biophys Res Commun. 2004;316:411-5 pubmed
    ..This is the first report to suggest that MEK1/2 phosphorylates not only ERK1/2 but also GSK-3beta. ..
  9. request reprint
    Takahashi Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, et al. Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem. 2006;281:38489-97 pubmed
    ..These results suggest that DIF-3 induces degradation of cyclin D1 through the GSK-3beta- and DYRK1B-mediated threonine phosphorylation in HeLa cells. ..